Smart health technology provider Alcidion Group has today announced the strategic acquisition of ExtraMed, a UK company which specialises in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow. 
Oxehealth has announced another world first after the US Food and Drug Administration granted a De Novo clearance for its Oxehealth Vital Signs product, which is incorporated into Oxevision, the vision-based patient monitoring and management platform delivered as software as a service. 
CliniSys Group has created a single brand for its businesses in the UK and Europe, with a refreshed logo and a new website.
The move creates a unified identity for CliniSys in the UK and MIPS on the continent and underlines the group's commitment to providing end-to-end diagnostic systems to support safe and effective healthcare systems today and to drive medical innovation in the future.
Thousands of NHS professionals across five hospitals in East Lancashire are to benefit from early warning technology that will help them detect and swiftly respond to deteriorating patients in need of urgent attention.
Alcidion's Patientrack system will help staff intervene early to prevent harm when patients show signs of worsening conditions.
Elsevier, together with Boehringer Ingelheim, Eli Lilly and Company, Pierre Fabre, Sanofi, Servier and others, has further refined and extended its drug-drug interaction risk calculator (DDIRC) within PharmaPendium. The DDIRC 2.0 aims to help scientists improve patient safety and effectively manage drug-drug interaction (DDI) risks across the drug development process. 
The Elisabeth-TweeSteden Hospital (ETZ) based in Tilburg and Waalwijk in the Netherlands is adopting a new digital training platform. It helps clinical staff optimize the use of its electronic patient dossier (EPD) system, Epic®. The healthcare organization is rolling out ANCILE Solutions’ uPerform platform after successful completion of an initial project in 2020. 
Abbott (NYSE: ABT) announced the U.S. launch of NeuroSphere™ Virtual Clinic, a first-of-its-kind technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed. Approved by the U.S. Food and Drug Administration, the NeuroSphere Virtual Clinic has the potential to 